Dicerna Pharmaceuticals (DRNA) is a small-cap ($980M) developing RNA interference (RNAi) based therapeutics for rare and/or chronic diseases affecting the kidney and liver.
The mechanism of RNAi was first described in the late 1990s by Drs. Andrew Fire and Craig Mello. In 2006, the Nobel Prize community acknowledged the paradigm-changing seminal concept by jointly awarding both scientists the 2006 Nobel Prize for Physiology or Medicine. Their mechanism of degrading mRNA from a specific gene proposed that:
RNA interference is activated when RNA molecules occur as double-stranded pairs in the cell. Double-stranded RNA activates biochemical machinery which degrades those mRNA molecules that carry a genetic code identical to that of the double-stranded RNA. When such mRNA molecules disappear, the corresponding gene is silenced and no protein of the encoded type is made.
Two decades following the seminal mechanistic discovery, the first RNAi based therapeutics, Onpattro (patisiran) by Alnylam Pharmaceuticals (ALNY) was approved by the FDA in 2018. To understand how competitive this technology could become, look no further than the 2017 legal tussle over RNAi trade secrets between Alnylam and Dicerna. Apparently, this issue has now been resolved with both sides claiming the usual "no wrongdoing".
Dicerna has created a proprietary RNAi technology platform, GalXC, "a next-generation RNAi-based therapies designed to silence disease-driving genes in the liver. GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. By using the Dicer enzyme as the entry point into the RNAi, we seek to optimize the activity of the RNAi pathway so that it operates in the most specific and potent fashion. Compounds produced via GalXC are intended to be broadly applicable across multiple therapeutic areas, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases."
It has a diverse pipeline with drug candidates in preclinical studies and at different phases of clinical development. The most advanced pipeline, DCR-PHXC, a breakthrough drug designate, is in Phase 3 study for the Primary Hyperoxaluria, a potential rare end-stage kidney disease, which is characterized by the recurrent kidney and bladder stones. Other drug candidates are DCR-HBVS and DCR-A1AT for chronic hepatitis B infection and alpha-1 antitrypsin deficiency-associated (A1AT) liver disease, respectively.
Alpha-1 antitrypsin deficiency (A1AT) is a genetic disorder that affects the liver and lungs. A1AT is caused by a mutation in the SERPINA1 gene. Alpha-1 antitrypsin protein regulates the effects of neutrophil elastase, an enzyme released from white blood cells to fight infection. Neutrophil elastase can induce chronic uninhibited tissue breakdown in the lung alveoli if not tightly controlled by alpha-1 antitrypsin.
Abnormal alpha-1 antitrypsin can also accumulate in the liver causing damage. A1AT can present from birth to old age and is the most frequent cause of metabolic liver disease in pediatric patients and the second most common indication for liver transplantation after biliary atresia. Suggesting that Alpha-1 antitrypsin induces protective effects in the lungs and liver against damage. Exposure to tobacco smoke, chemicals, and dust has been proposed to impact the severity of A1AT.
NIH notes that:
10% of infants with A1AT develop liver disease, which often causes yellowing of the skin and whites of the eyes (jaundice). Approximately 15% of adults with A1AT develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.
The disorder affects about 120,000 European individuals or 1 in 1,500 to 3,500 individuals with European ancestry with many more being undiagnosed, particularly people with a lung condition called chronic obstructive pulmonary disease.
Therapeutics: Four alpha-1 antitrypsin products derived from a human plasma Prolastin, Zemaira, Glassia, and Aralast are approved by the FDA as intravenous augmentation A1AT therapy, costing up to $100,000 annually per patient. Alternative strategies currently being investigated, includes new delivery strategies, the use of gene therapy or Induced pluripotent stem cells (iPSCs), and silencing RNA strategies.
In Q3/2019, DRNA announced:
Initiation of a multi-center Phase 1/2 trial of DCR-A1AT is expected in the third quarter of 2019. The proposed parallel-group, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DCR-A1AT in adult healthy volunteers (HVs) and patients with A1AT deficiency-associated liver disease.
At the end of Q2/2019, DRNA reported that cash and cash equivalents were $345.3M. DRNA perceives it has sufficient funds to execute current clinical trials and other operating expenses beyond 2020. DRNA has ongoing collaborative license agreements with Eli Lilly (LLY), Alexion (ALXN) and Boehringer Ingelheim International.
With 3 clinical-stage programs, several catalytic events are expected in 2020 and beyond.
RNAi-based therapeutics are high risk due to potential safety and tolerability signals. In 2016, ALNY halted further clinical development of Phase 3 drug candidate, revusiran, for treating a rare and fatal disorder called ATTR amyloidosis with cardiomyopathy, due to safety signals.
It has been proposed that the GalXC-Dicer enzyme RNAi platform invented by DRNA is designed to use the lowest possible dose whilst providing therapeutic efficacy and improved safety profile. Additional risks that could negatively impact the share price are negative data readout from clinical trials.
Institutional ownership currently stands at 82.35%, with 116 institutional holders accounting for 56,295,099 total shares. Analysts recommend a strong buy with a 12-month consensus price target of $22.25.
CEO & President Doug Fambrough on executing DRNA clinical and financial strategy:
The first aspect of the strategy is to go deep on select opportunities addressing a high unmet medical need with what we believe is a high probability of clinical and commercial success.
Our internal clinical pipeline reflects these choices including two rare diseases, primary hyperoxaluria and alpha-1 antitrypsin deficiency-associated liver disease, where we plan to drive development and commercialization either wholly or largely on our own and one prevalent disease, chronic hepatitis B virus infection, where we are seeking a development and commercialization partner, concomitant with Phase 1 proof-of-concept data.
The second aspect of the strategy is to realize the potential of our technology against all remaining targets through collaboration and discovery stage licensing with therapeutic area leaders. Our collaborations with Eli Lilly, Alexion and Boehringer Ingelheim reflect this aspect of our strategy. It is our expectation and plan that we will expand on both aspects of the strategy in coming quarters, both expanding our internal pipeline and expanding our circle of corporate collaborators, funding for much will help us drive the internal pipeline.
Thanks for reading. While I occasionally cover companies like this, my focus remains investment opportunities in liver therapeutics, specifically NASH and Cholestatic liver diseases, which are exclusive to members of my private investing community, Liver Therapy Forum Marketplace.
As a Ph.D. trained liver biomedical scientist & Scientific Consultant, I provide:
Novel mechanistic insights and "updating thesis" highlighting promising drug candidates.
Exclusive access to full-length in-depth research analytical articles, KOL interviews, newsletters/digests, and Q & A chat board.
Actionable events to minimize risks and grow your investments.
Knowledge and wisdom required to understand the diverse and complex NASH therapeutics landscape.
Sign-up today to grow your investments!
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: As always, my articles are meant to facilitate your understanding. Readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. Investing in common stock can result in partial or total loss of capital. Please implement due diligence and invest wisely.
See the original post here:
Dicerna And DCR-A1AT In Alpha-1 Antitrypsin Deficiency-Associated Liver Disease - Seeking Alpha
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 27th, 2020
- Induced Pluripotent Stem Cells Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis... - November 27th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Applications, Types and Future Ou - News by aeresearch - November 27th, 2020
- Research Paper Showing ProtoKinetix AAGP Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision - Business Wire - November 27th, 2020
- Induced Pluripotent Stem Cells Market 2020: Enhanced Growth, Recent Trends and Major Companies are Fujifilm Holding Corporation, Astellas Pharma, Fate... - November 27th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 27th, 2020
- Astronaut Soichi Noguchi still adapting to life on ISS - The Japan Times - November 27th, 2020
- Potential new therapies for Alzheimer's disease are revealed through network modeling of its complex molecular interactions - Science Codex - November 27th, 2020
- Global Induced Pluripotent Market To Perceive Biggest Trend And Opportunity With Key Players CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher... - November 22nd, 2020
- Global Stem Cell Banking Market 2020: Overview, Trends, Opportunities, Impact of Drivers, Key Vendors, Types, Applications, Forecast by Focusing... - November 22nd, 2020
- Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand - BSA bureau - November 20th, 2020
- Neurons stripped of their identity are hallmark of Alzheimer's disease, study finds - National Science Foundation - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Stem Cells Market Value Expected To Reach $17.79 Billion By 2027 - Eurowire - November 20th, 2020
- How regenerative medicine could be used to contain COVID-19, others - Guardian - November 20th, 2020
- The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24 - November 18th, 2020
- at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Fred Hutch News Service - November 18th, 2020
- Neurons stripped of their identity are hallmark of Alzheimers disease, study finds - Newswise - November 18th, 2020
- Genetic influences on viral-induced cytokine responses in the lung - DocWire News - November 18th, 2020
- Japanese and U.S. astronauts arrive at ISS in SpaceX ship - The Japan Times - November 18th, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - BioSpace - November 18th, 2020
- Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -... - November 12th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -... - November 12th, 2020
- Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace - November 12th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -... - November 12th, 2020
- Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,... - November 12th, 2020
- Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics... - November 12th, 2020
- Induced Pluripotent Stem Cells Industry Market 2020 Global Trends, Key Players, Share, Growth, Analysis, Opportunities and Forecast To 2026 -... - October 31st, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 31st, 2020
- In Vitro Toxicology Testing Market: Facts, Figures and Analytical Insights, 2018 to 2024 - Aerospace Journal - October 31st, 2020
- Bayer Acquires AskBio to Expand Gene Therapy Platform - PharmaLive - October 31st, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast... - October 29th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By... - October 29th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis by Size: 2025, Impact of Covid-19 on Industry Chain, Market Growth, Drivers | Business Overview... - October 29th, 2020
- The Induced Pluripotent Stem Cells Market To Witness A Major Breakthrough In The Form Of A Double-Digit CAGR Of 7% - KYT24 - October 29th, 2020
- Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against... - October 29th, 2020
- QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board - BioSpace - October 29th, 2020
- AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute... - October 29th, 2020
- Bayer Acquires AskBio for Up to $4 Billion to Expand Gene Therapy Platform - BioSpace - October 29th, 2020
- How Will the Virus Epidemic Cause Induced Pluripotent Stem Cells (iPSCs) Market 2020 - The Think Curiouser - October 24th, 2020
- Trends in the Ready To Use Induced Pluripotent Stem Cells Market 2020-2020 - Eurowire - October 24th, 2020
- Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire - October 24th, 2020
- The Induced Pluripotent Stem Cells Market To Mark Robustness In The Form Of A Robust CAGR - KYT24 - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Kobe Hospital Trials Transplant to Reverse Blindness A First in the World - JAPAN Forward - October 23rd, 2020
- Rethinking the Link between Cannabinoids and Learning - Lab Manager Magazine - October 23rd, 2020
- Cold sore virus can spread to unborn babies harming their brains, docs warn - The Sun - October 23rd, 2020
- Microscopy Beyond the Resolution Limit - Lab Manager Magazine - October 21st, 2020
- AMSBIO Launches New Human iPSC-Derived Cells and iPSC Differentiation Reagent Kits - Technology Networks - October 20th, 2020
- Induced Pluripotent Stem Cells Market To Grow At 7% YOY In Forecast Years 2026 - The Think Curiouser - October 20th, 2020
- Groundbreaking eye surgery in Kobe offers hope to sight impaired : The Asahi Shimbun - Asahi Shimbun - October 20th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - PRnews Leader - October 16th, 2020
- Induced Pluripotent Stem Cells Market 2020 Is Slated to Grow Rapidly in the Forthcoming Years with Key Players Addgene, Axol Bioscience, Cell... - October 16th, 2020
- Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation - BioSpace - October 16th, 2020
- Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome... - October 16th, 2020
- Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum - October 16th, 2020
- Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry - BioSpace - October 16th, 2020
- Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting - GlobeNewswire - October 16th, 2020
- Global Stem Cell Therapy Market 2020: Trends, and Opportunity Analysis, Top Manufacturers And Forecast to 2027 - PRnews Leader - October 16th, 2020
- Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients |... - October 8th, 2020
- Dolly the Sheep: '90s Media Sensation - Mental Floss - October 8th, 2020
- Regeneron, Pfizer and BioNTech Accused of Infringing Allele Patent in Connection with COVID-19 Technologies - IPWatchdog.com - October 8th, 2020
- Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online - October 7th, 2020
- Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing... - October 7th, 2020
- Huge Investment in Induced Pluripotent Stem Cells Market Expected to Witness the Highest Growth 2026 | Fujifilm Holding Corporation (CDI) Ncardia,... - October 3rd, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 3rd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 29th, 2020
- ONLINE: The Future of Medicine - Isthmus - September 29th, 2020
- funded study sheds light on abnormal neural function in rare genetic disorder - National Institutes of Health - September 29th, 2020
- Stem Cell Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle - September 29th, 2020
- The new pharma collaborations driving transformative research in oncology - - pharmaphorum - September 29th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate... - September 21st, 2020
- Induced Pluripotent Stem Cells Market to Witness Huge Growth by 2025| Bone Therapeutics SA, System Biosciences, Axiogenesis, Regeneus Ltd.,... - September 14th, 2020
- Global Stem Cells Market Report, History And Forecast 2020-2027, Breakdown Data By Manufacturers, Key Regions, Types And Application - Bulletin Line - September 11th, 2020
- New DNA Recovery Technique Reveals Richer Picture of the Past - Lab Manager Magazine - September 11th, 2020
- Study Identifies New Set of Genes That May Explain Why People with Down Syndrome Have a Higher Risk of Leukemia - DocWire News - September 10th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 10th, 2020
- Scientists May Have Discovered a Way to to Slow Aging by Direct Reprogramming of Human Cells - SciTechDaily - September 10th, 2020
- Induced Pluripotent Stem Cells Market Global Growth Analysis and Forecast to 2024 | Top Players (BlueRock Therapeutics, Corning Life Sciences, EMD... - September 10th, 2020
- Study: The Speed Neurons Fire Impacts Their Ability to Synchronize - Lab Manager Magazine - September 10th, 2020